Cingulate Inc. Showcases CTx-1301 at Prestigious Event
Cingulate Inc. (NASDAQ: CING), a dynamic biopharmaceutical company, has exciting news for those following advancements in ADHD treatment. The company's lead candidate, CTx-1301, recently received recognition with a coveted podium presentation at a significant meeting of experts in child and adolescent psychiatry. This opportunity showcases the innovative research surrounding CTx-1301, a formulation designed specifically to offer simplified treatment for individuals grappling with ADHD.
Key Details about CTx-1301 Presentation
The eagerly awaited session will feature Dr. Ann Childress, a prominent figure in the ADHD community and a past president of the American Professional Society of ADHD and Related Disorders (APSARD). Dr. Childress will detail the Phase 3 clinical trial results in her presentation titled "Efficacy and Safety of CTx-1301 in Pediatric Subjects With ADHD." This presentation is set to deliver vital insights into the promising effects of this medication.
Importance of the Conference
Dr. Childress expressed her enthusiasm for this presentation, stating, "We look forward to presenting the results of this pivotal trial at AACAP, a premier scientific forum for child and adolescent psychiatry." Her insights promise to enhance understanding of how CTx-1301 can relieve symptoms while simplifying dosing requirements for patients.
Statements from Cingulate Leadership
Adding to the excitement, Dr. Raul Silva, Cingulate's Chief Science Officer, noted the importance of this recognition: "Selection for an AACAP podium presentation is a meaningful acknowledgment of the scientific rigor behind our Phase 3 program." This statement reinforces Cingulate's commitment to addressing the challenges faced by those who utilize current stimulant therapies, such as inconsistent coverage and multiple daily doses.
ADHD: A Persistent Challenge
Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent condition that affects around 20 million people in the country, including millions of children. Symptoms like inattention, hyperactivity, and impulsivity can significantly impair daily functioning across various aspects of life. Traditional stimulant medications are considered the gold standard for treatment but often lead to complicated dosing schedules that are not always effective in maintaining symptom relief throughout the day.
Understanding CTx-1301
CTx-1301, a once-daily multi-core tablet, employs Cingulate's proprietary Precision Timed Release™ (PTR™) technology, allowing it to deliver three timed releases of medication throughout the day. This innovative design seeks to ensure swift symptom relief and efficacy throughout the active hours, an improvement many ADHD sufferers have long awaited.
About Cingulate Inc.
Cingulate Inc. is at the forefront of biopharmaceutical innovations, focusing on developing advanced therapeutic solutions that enhance patient outcomes. With CTx-1301 in late-stage development for ADHD, the company is also exploring additional pipelines targeting anxiety and other neuropsychiatric disorders. Headquartered in Kansas City, Cingulate's dedication to improving patient quality of life through effective treatments remains paramount.
Dr. Ann Childress: A Leader in Psychiatry
Dr. Ann C. Childress brings over 35 years of experience in psychiatry, focusing on ADHD treatment. Her impressive credentials include numerous roles in academic and clinical settings, underscoring her expertise in the field. As a leading investigator, Dr. Childress has played a crucial role in shaping the clinical trials for CTx-1301, ensuring that research is guided by a wealth of knowledge and experience.
Frequently Asked Questions
What is CTx-1301?
CTx-1301 is a once-daily medication designed for treating ADHD, utilizing a unique drug-delivery platform for effective dosing.
Who will present the data on CTx-1301?
Dr. Ann Childress, a well-known ADHD specialist, will present the Phase 3 study results at the AACAP Annual Meeting.
What are the benefits of CTx-1301 compared to other treatments?
CTx-1301 offers once-daily dosing and aims to provide consistent symptom relief throughout the day, addressing challenges with current stimulant therapies.
Where can I find more information about Cingulate?
More details about Cingulate and its products can be found on their official website, Cingulate.com.
When will the AACAP presentation take place?
The presentation is scheduled for October 24, 2025, and will be a significant part of the AACAP's sessions.
